Bristol-Myers Squibb (BMY) Appoints Paul Biondi Senior Vice President, Head Of Business Development


NEW YORK--(BUSINESS WIRE)--Today, Bristol-Myers Squibb Company (NYSE: BMY) announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to Charlie Bancroft, chief financial officer. In this role, Biondi will lead the development of strategic partnerships and pursue scientific innovations across commercial, development, discovery and technology platforms to complement the company's internal R&D pipeline. Biondi most recently served as senior vice president, head of R&D Operations, Bristol-Myers Squibb.

"Business development is a key component of Bristol-Myers Squibb's strategy, and has strengthened and diversified our portfolio for long-term growth"

"Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made significant contributions over the past 10 years to our success in R&D and business development," said Bancroft. "With deep knowledge of our R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is the ideal leader to continue our pursuit of external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases."

"Business development is a key component of Bristol-Myers Squibb's strategy, and has strengthened and diversified our portfolio for long-term growth," said Biondi. "We have been successful in executing transactions that make sense strategically, scientifically and economically for our company and partners. I look forward to leading this high-performing team and continuing our pursuit of collaborative partnerships and scientific innovation to help patients."

As head of R&D Operations, Biondi led an organization focused on optimizing delivery of the company's pipeline, managing the company's R&D portfolio and project management as well as early- and late-stage clinical operations providing strategic insights and operational excellence across R&D. He also had responsibility for cross R&D efforts around strategy, analytics, continuous improvement, learning and collaboration. Biondi served a member of Bristol-Myers Squibb R&D Senior Leadership Team, Deal Review Committee and is a member of the board of directors of Transcelerate Biopharma Inc.

Biondi joined Bristol-Myers Squibb in 2002 and was appointed vice president of R&D Operations when it was formed in May 2005. He was promoted to senior vice president of R&D Operations in 2010 and has taken on increasing levels of responsibility.

Biondi holds a bachelor's degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit or follow us on Twitter at


Bristol-Myers Squibb
Ken Dominski, 609-252-5251
[email protected]
Laura Hortas, 609-252-4587
[email protected]
Ranya Dajani, 609-252-5330
[email protected]

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.